Human Albumin Csl Behring

Human Albumin CSL Behring is a sterile solution for injection that contains human plasma protein (albumin) as its active ingredient; the product’s strength is not specified in the available data. It is classified as a plasma‑derived volume expander and is supplied in a ready‑to‑use intravenous solution. The preparation is marketed in the European Union and is available by prescription only for clinical use in hospitals and specialized care settings.

Human Albumin CSL Behring is indicated for several clinical situations in which plasma oncotic pressure is reduced or intravascular volume needs rapid restoration.

- Hypovolemia due to acute blood loss or dehydration. - Shock associated with severe sepsis or trauma. - Major burns requiring fluid resuscitation. - Hypoalbuminemia secondary to liver disease, nephrotic syndrome, or malnutrition. - Peri‑operative volume support in cardiac surgery or liver transplantation. - Patients undergoing renal dialysis who develop low plasma albumin.

Adverse reactions to Human Albumin CSL Behring are generally infrequent, but they can range from mild infusion‑related events to rare severe hypersensitivity responses.

Common: - Transient fever or chills occurring during or shortly after the infusion. - Mild headache or dizziness that resolves without intervention. - Nausea or vomiting, usually limited to the infusion period. - Localized erythema, warmth, or swelling at the catheter or infusion site.

Serious: - Anaphylactic or severe allergic reaction, presenting with urticaria, bronchospasm, hypotension, or angioedema. - Volume overload resulting in pulmonary edema, particularly in patients with pre‑existing cardiac or renal disease. - Hemolysis or acute kidney injury secondary to rapid intravascular volume expansion. - Transmission‑related infection, a theoretical risk that is extremely rare with modern purification processes.

When prescribing Human Albumin CSL Behring, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

- Assess cardiac function; avoid use in uncontrolled heart failure or severe pulmonary hypertension. - Evaluate renal function; patients with chronic kidney disease may be prone to volume overload. - Monitor for signs of fluid overload, especially during rapid or large‑volume infusions. - Use caution in patients with known hypersensitivity to human albumin or any component of the formulation. - Consider the risk of infection; ensure the product is stored and handled according to aseptic guidelines. - Adjust dosage in patients with severe hypoalbuminemia secondary to liver disease, balancing oncotic benefit against potential overload.

Human Albumin CSL Behring may influence the pharmacokinetics of concomitant medications and can interact with agents that affect fluid balance.

Avoid: - Concurrent administration of other volume expanders (e.g., synthetic colloids) that may exacerbate volume overload. - High‑dose diuretics without close monitoring, which can precipitate rapid shifts in intravascular volume. - Medications that increase capillary permeability (e.g., high‑dose steroids) when aggressive volume expansion is not desired.

Use with caution: - Vasopressor agents, as albumin‑induced volume expansion may alter dosing requirements. - Anticoagulants, because changes in plasma volume can affect coagulation parameters. - Renin‑angiotensin‑aldosterone system inhibitors, which may modify blood pressure responses during infusion.